Phase 2b Study to Evaluate Weight Management Using Macupatide and Eloralintide Alone or Together in Adults With Obesity or Overweight Without Type 2 Diabetes

What this Trial Is About

Researchers are evaluating the effects of macupatide and eloralintide, alone or combined, on body weight reduction in adults with obesity or overweight who do not have type 2 diabetes. This Phase 2b clinical trial aims to study the weight-lowering effectiveness and safety of these drugs compared with placebo under a randomized, double-blind, placebo-controlled design. Participants are assigned to one of several groups receiving macupatide, eloralintide, both drugs together, or placebo, all administered by subcutaneous injection. The study lasts about 64 weeks, including treatment and follow-up periods, with dosing at different levels and combinations to assess the interventions effects on weight management. During the study, participants undergo regular visits for assessments including body weight measurements up to at least week 36 and beyond. Researchers monitor changes in body weight, body mass index BMI, and the proportion of participants who achieve significant weight loss percentages. Safety and adherence are also tracked throughout the trial to evaluate the treatments over the full participation period.

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight